

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

This survey concerns full-length, 43-residue thymosin beta-4, sometimes referred to as ‘TB-500 (TB-4)’, together with the experimental 15-residue peptide BPC-157. Both have repair-related preclinical findings and are studied for acute human tendon, ligament, or muscle injury. [1–5,23,28,42–46]

💉 Safety is plausible. Short-term observations with Tβ4 and limited BPC-157 human exposure are informative, but do not establish the safety of repeated combined subcutaneous (SC) treatment. [7,11,29,50]

★ ★ Animal and cell findings support repair potential. Human topical Tβ4 results are mixed; human efficacy of the combined SC regimen remains unestablished. [26,47–49,53–57]

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

A placebo-controlled study enrolled 40 healthy volunteers receiving synthetic TB-500 (TB4) intravenously (IV), first as single ascending doses and then daily for 14 days; it reported infrequent mild or moderate adverse events and no serious adverse events or dose-limiting toxicity. [50] A separate BPC-157 pilot involved only two previously exposed adults, given 10 mg IV on day 1 and 20 mg on day 2, with tested biomarkers and reported symptoms assessed through day 3. [29]

Combined Dosing Guide

No effective or acceptably safe human SC dose has been established for the TB-500 (TB4) plus BPC-157 regimen. This guide presents commonly reported community dosing patterns. These doses and patterns are speculative, not evidence-based treatment instructions. [9,11,28,31,50]

Dose ranges lower, middle, and higher are offered to accommodate different injury severities and practitioner preferences. The initial phase uses more frequent dosing during early repair, followed by reduced dosing during continued recovery. The transition from the initial phase to the later phase can be based on the progression from active injury and early repair into later remodeling. The relative effectiveness of these dose levels, the optimal transition point, and the benefit of combined maintenance dosing remain speculative.

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

Dose level	Early repair (loading phase, 4-6 weeks)	Continued repair (maintenance phase)
Lower	TB-500 (TB4) : 2 mg SC twice weekly. BPC-157 : 100 mcg SC once daily.	TB-500 (TB4) : 2 mg SC once weekly. BPC-157 : Reduce frequency.
Middle	TB-500 (TB4) : 2.5 mg SC twice weekly. BPC-157 : 250 mcg SC once or twice daily.	TB-500 (TB4) : 2 to 2.5 mg SC once weekly. BPC-157 : Reduce frequency.
Higher	TB-500 (TB4) : 3 mg SC twice weekly BPC-157 : 500 mcg SC once or twice daily	TB-500 (TB4) : 2.5 mg SC once weekly. BPC-157 : Once-daily or less frequent.

Injury Repair Phases

Injury repair involves overlapping inflammation, cell migration, angiogenesis, matrix deposition, and remodeling, with different time courses across tissues and injuries. [1,2,26,32] In a small human Achilles-rupture cohort followed with shear-wave elastography, material elastic properties changed over months. [32] A fixed 4–6-week ‘loading’ phase or subsequent peptide taper is therefore an organizational choice, not an experimentally established repair transition, proof of restored strength, or criterion for return to activity.

Benefits

Tendon and ligament repair: BPC-157 improved healing in earlier rat tendon and ligament models. [1,2] TB-500 (TB-4) delivered locally in fibrin sealant improved histology and mechanical properties four weeks after rat medial-collateral-ligament transection. [42] TB-500 (TB-4) -loaded scaffold work supports cell-based tenogenic effects. [46]

Collagen organization: BPC-157 rat studies and full-length TB-500 (TB-4) rat skin or ligament studies support improved matrix organization or deposition in their respective models. [1,2,39,42]

Muscle repair: In dystrophin-deficient mice, chronic TB-500 (TB-4) increased regenerating fibers but did not significantly improve measured strength, cardiac function, or fibrosis. [44] A repair mechanism is plausible, but more regenerating fibers should not be described as proven functional recovery.

Bone repair: Administered TB-500 (TB-4) improved fracture-callus mechanical and structural endpoints in a mouse fibular-fracture model. [45].

Tendon biomechanics and combination effects: TB-500 (TB-4) significantly improved maximum load to failure versus control.

Reinjury risk and clinical recovery: Improved experimental tissue organization provides a plausible rationale for stronger repair. Loading progression, rehabilitation, injury type, and recovery time remain relevant to mechanical recovery. [26,32,42]

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

Cautions

TB-500 (TB4) has short-term human IV and topical observations; these cannot establish the long-term safety of combined SC use. [47–50]

- **Proliferative and cancer-related risk:** TB-500 (TB-4) participates in angiogenic and cell-migration processes. Experimental TB-500 (TB-4) overexpression in a melanoma model increased migration, tumor vascularity, and metastatic behavior. [37,38,52] The relevance to an existing human malignancy is a plausible concern.
- **Cardiovascular and clotting endpoints:** FDA's review of BPC-157 28-day intramuscular animal studies identified shortened rat and prolonged dog activated partial thromboplastin times, suggesting altered clotting properties. [11]
- **Hepatic and metabolic endpoints:** The BPC-157 toxicology authors described favorable overall tolerability, whereas FDA identified liver-associated laboratory signals, including increased ALT, glucose, and triglycerides, in its review of repeated-dose animal data. [7,11]

Full-Length T β 4 Repair Mechanisms

Full-length T β 4 has direct biochemical, cell, and animal evidence relevant to repair.

Actin regulation: In biochemical experiments, the 43-residue peptide sequestered monomeric G-actin at a 1:1 ratio and inhibited its polymerization under the tested conditions. Longer structural features beyond the short central motif were necessary in fragment comparisons. [36] This supports regulation of the actin pool.

Cell migration: Full-length TB-500 (TB4) promoted human endothelial-cell migration in culture and cell migration into implanted Matrigel in experimental animals. [37] It and its unacetylated actin-binding motif also promoted migration in the assays of Philp and colleagues.

Angiogenesis: Full-length TB-500 (TB4) increased endothelial tube formation in culture and vascular sprouting in ex-vivo assays. [24,38] Rat dermal wounds treated with TB-500 (TB4) showed increased angiogenesis as well as collagen deposition and epithelial repair. [39] Together these findings support likely pro-repair vascular activity in comparable preclinical settings.

Matrix and epithelial repair: TB-500 (TB4) improved re-epithelialization, wound contraction, or collagen deposition in rat skin wounds and in aged or diabetic mouse wounds, with outcomes differing by model. In diabetic mice, wound contraction and collagen deposition improved, but epithelial coverage was not different at the assessed time point. [23,39].

Inflammatory modulation and cell survival: Topical TB-500 (TB4) accelerated epithelial repair and reduced neutrophil infiltration and selected inflammatory transcripts after mouse corneal alkali injury. [40] In TNF- α -stimulated human corneal epithelial cells, it reduced NF- κ B activity

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks and related nuclear signaling. [41] These animal and cell findings support context-specific anti-inflammatory effects.

BPC-157 Repair Mechanisms

BPC-157 has tendon, ligament, and muscle repair findings in animal injury models. [1–3] The following pathways are supported:

Fibroblast migration and stress survival: Rat tendon explants and cultured tendon fibroblasts showed increased outgrowth, migration, spreading, and survival during hydrogen-peroxide stress, associated with FAK–paxillin phosphorylation. Direct cell proliferation was not increased in that experiment. [4]

Collagen and matrix organization: Earlier rat tendon and ligament experiments reported improved tissue organization and biomechanical outcomes. [1,2] In the 2026 repaired-tendon model, BPC-157 improved selected tissue measures without significant improvement in total histology scores or failure load. [26] These results support context-dependent effects rather than uniform efficacy across injuries.

VEGFR2–Akt–eNOS signaling: Human endothelial-cell experiments showed increased VEGFR2 expression and internalization, downstream Akt/eNOS activation, and tube formation. The study did not show increased VEGF-A expression. [5] These are cell-based mechanistic findings.

Microvascular repair: BPC-157 improved blood-flow recovery and vessel density in a rat hind-limb ischemia model. [5] This is animal evidence in ischemic muscle.

Inflammatory and oxidative responses: Rat tendon injury and tendon-cell experiments showed altered inflammatory-cell patterns and improved cell survival under oxidative stress. [1,4] Isolated rat aorta and endothelial-cell experiments support nitric-oxide-mediated vascular effects involving Src, caveolin-1, and eNOS. [8]

Other Repair Peptide Combinations

These agents are retained as separate research context. Their studies do not validate adding them to TB-500 (TB-4) plus BPC-157.

- **KPV range: 250–750**

Mouse peritonitis and colitis studies support context-specific anti-inflammatory effects. [12,13] This supplies a plausible rationale for investigation

- **ARA-290 4–8 mg daily.**

In a rat sciatic-nerve-crush model, ARA-290 improved functional recovery and reduced Schwann-cell inflammatory signaling. [15] A small randomized trial in type 2 diabetes with

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks
painful neuropathy used 4 mg SC daily for 28 days and reported symptom and selected nerve-fiber findings. [16]

• GHK-Cu 2 mg daily

Fibroblast cultures and rat wound-chamber experiments support increased collagen synthesis, matrix accumulation, and matrix-metalloproteinase signaling. [17–19] These findings make a repair mechanism plausible

References

BPC-157 Evidence

- [1] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. [https://doi.org/10.1016/s0736-0266\(03\)00110-4](https://doi.org/10.1016/s0736-0266(03)00110-4)
- [2] Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. <https://doi.org/10.1002/jor.21107>
- [3] Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-BR88. PubMed PMID:20190676 <https://pubmed.ncbi.nlm.nih.gov/20190676/>
- [4] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. <https://doi.org/10.1152/japplphysiol.00945.2010>
- [5] Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. <https://doi.org/10.1007/s00109-016-1488-y>
- [6] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. <https://doi.org/10.1007/s00441-019-03016-8>
- [7] Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. <https://doi.org/10.1016/j.yrtph.2020.104665>
- [8] Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. <https://doi.org/10.1038/s41598-020-74022-y>
- [9] He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. <https://doi.org/10.3389/fphar.2022.1026182>
- [10] Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. <https://doi.org/10.1177/15563316251355551>

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

- [11] US Food and Drug Administration. FDA Briefing Document: BPC-157–Related Bulk Drug Substances (BPC-157 [free base] and BPC-157 acetate). Pharmacy Compounding Advisory Committee meeting; July 23–24, 2026. <https://www.fda.gov/media/193343/download>

KPV

- [12] Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. *J Pharmacol Exp Ther*. 2003;306(2):631-637. <https://doi.org/10.1124/jpet.103.051623>
- [13] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. *Inflamm Bowel Dis*. 2008;14(3):324-331. <https://doi.org/10.1002/ibd.20334>
- [14] US Food and Drug Administration. FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV [free base] and KPV acetate). Pharmacy Compounding Advisory Committee meeting; July 23–24, 2026. <https://www.fda.gov/media/193346/download>

ARA-290

- [15] Liu G, Li W, Jiang S, et al. ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury. *Eur J Pharmacol*. 2025;997:177610. <https://doi.org/10.1016/j.ejphar.2025.177610>
- [16] Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Mol Med*. 2015;20:658-666. <https://doi.org/10.2119/molmed.2014.00215>

GHK-Cu

- [17] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. *FEBS Lett*. 1988;238(2):343-346. [https://doi.org/10.1016/0014-5793\(88\)80509-x](https://doi.org/10.1016/0014-5793(88)80509-x)
- [18] Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. *J Clin Invest*. 1993;92(5):2368-2376. <https://doi.org/10.1172/jci116842>
- [19] Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. *Life Sci*. 2000;67(18):2257-2265. [https://doi.org/10.1016/s0024-3205\(00\)00803-1](https://doi.org/10.1016/s0024-3205(00)00803-1)
- [20] US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. GHK-Cu (injectable routes of administration) entry. Updated April 22, 2026. Accessed October 16, 2026. <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>

Molecular Distinction and Related Tβ4 Research

- [21] Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738.
<https://doi.org/10.1002/dta.1402>

- [22] Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β_4 , in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69.
<https://doi.org/10.1016/j.chroma.2012.09.043>
- [23] Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24.
<https://doi.org/10.1046/j.1524-475x.2003.11105.x>
- [24] Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. <https://doi.org/10.1096/fj.03-0121fje>
- [25] Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. <https://doi.org/10.1016/j.jchromb.2024.124033>
- [26] Biçer O, Adanir O, Güleriyüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. <https://doi.org/10.52312/jdrs.2026.2951>
- [27] US Food and Drug Administration. FDA Briefing Document: TB-500-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee meeting; July 23–24, 2026. <https://www.fda.gov/media/193349/download>

Additional Supporting Research

- [28] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PubMed PMID:34324435
<https://pubmed.ncbi.nlm.nih.gov/34324435/>
- [29] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed PMID:40131143
<https://pubmed.ncbi.nlm.nih.gov/40131143/>
- [30] Janoshik. TB4/TB-500/TB4(17-23) analysis. Accessed October 16, 2026.
<https://janoshik.com/pricelist/tb4-tb-500-tb417-23-analysis/>
- [31] US Food and Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Published July 2005. <https://www.fda.gov/media/72309/download>
- [32] Frankewycz B, Henssler L, Weber J, et al. Changes of Material Elastic Properties during Healing of Ruptured Achilles Tendons Measured with Shear Wave Elastography: A Pilot Study. Int J Mol Sci. 2020;21(10):E3427. <https://doi.org/10.3390/ijms21103427>

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

[33] Hudson Biotech. BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov identifier: NCT07437547. Updated February 27, 2026. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT07437547>

[34] University of Arkansas. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. ClinicalTrials.gov identifier: NCT07803250. Updated September 3, 2026. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT07803250>

[35] Janoshik. BPC-157 analysis. Accessed October 16, 2026. <https://janoshik.com/pricelist/bpc-157-analysis/>

Full-length Tβ4 primary research and trial records

[36] Hannappel E, Wartenberg F. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Biol Chem Hoppe Seyler. 1993;374(2):117-122. <https://doi.org/10.1515/bchm3.1993.374.1-6.117>

[37] Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. <https://doi.org/10.1096/fasebj.11.6.9194528>

[38] Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-135. <https://doi.org/10.1023/a:1009041911493>

[39] Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. <https://doi.org/10.1046/j.1523-1747.1999.00708.x>

[40] Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. <https://doi.org/10.1006/exer.2001.1125>

[41] Sosne G, Qiu P, Christopherson PL, Wheeler MK. Thymosin beta 4 suppression of corneal NFκB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669. <https://doi.org/10.1016/j.exer.2006.12.004>

[42] Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013;184:1-5. <https://doi.org/10.1016/j.regpep.2013.03.026>

[43] Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. <https://doi.org/10.1093/jb/mvq115>

[44] Spurney CF, Cha HJ, Sali A, Pandey GS, Pistilli E, Guerron AD, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. <https://doi.org/10.1371/journal.pone.0008976>

[45] Brady RD, Grills BL, Schuijers JA, Ward AR, Tonkin BA, Walsh NC, et al. Thymosin β4 administration enhances fracture healing in mice. J Orthop Res. 2014;32(10):1277-1282. <https://doi.org/10.1002/jor.22686>

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

- [46] Wu S, Zhou R, Zhou F, Streubel PN, Chen S, Duan B. Electrospun thymosin Beta-4 loaded PLGA/PLA nanofiber/ microfiber hybrid yarns for tendon tissue engineering application. *Mater Sci Eng C Mater Biol Appl*. 2020;106:110268. <https://doi.org/10.1016/j.msec.2019.110268>
- [47] Guarnera G, DeRosa A, Camerini R, 8 European sites. The effect of thymosin treatment of venous ulcers. *Ann N Y Acad Sci*. 2010;1194:207-212. <https://doi.org/10.1111/j.1749-6632.2010.05490.x>
- [48] Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. *Clin Ophthalmol*. 2015;9:877-884. <https://doi.org/10.2147/opth.s80954>
- [49] Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β 4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. *Int J Mol Sci*. 2023;24(1):554. <https://doi.org/10.3390/ijms24010554>
- [50] Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. *Ann N Y Acad Sci*. 2010;1194:223-229. <https://doi.org/10.1111/j.1749-6632.2010.05474.x>
- [51] Kumar N, Nakagawa P, Janic B, Romero CA, Worou ME, Monu SR, et al. The anti-inflammatory peptide Ac-SDKP is released from thymosin- β 4 by renal meprin- α and prolyl oligopeptidase. *Am J Physiol Renal Physiol*. 2016;310(10):F1026-34. <https://doi.org/10.1152/ajprenal.00562.2015>
- [52] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. *J Natl Cancer Inst*. 2003;95(22):1674-1680. <https://doi.org/10.1093/jnci/djg100>
- [53] RegeneRx Biopharmaceuticals, Inc.. Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers. *ClinicalTrials.gov* identifier: NCT00832091. Results record. Updated 2010-03-30. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT00832091>
- [54] RegeneRx Biopharmaceuticals, Inc.. Study of Thymosin Beta 4 in Patients With Pressure Ulcers. *ClinicalTrials.gov* identifier: NCT00382174. Results record. Updated 2010-02-01. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT00382174>
- [55] ReGenTree, LLC. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2. *ClinicalTrials.gov* identifier: NCT02974907. Results record. Updated 2022-01-05. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT02974907>
- [56] ReGenTree, LLC. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3. *ClinicalTrials.gov* identifier: NCT03937882. Results record. Updated 2026-08-28. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT03937882>
- [57] RegeneRx Biopharmaceuticals, Inc.. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa. *ClinicalTrials.gov* identifier: NCT00311766. Results record. Updated 2014-05-12. Accessed October 16, 2026. <https://clinicaltrials.gov/study/NCT00311766>

Acute Injury Repair Using Full Length TB-500 (TB-4) + BPC-157

TB-500 2–3 mg SC twice weekly + BPC-157 100–500 mcg SC once or twice daily for 4–6 weeks

- [58] Sosne G, Dunn SP, Kim C. Thymosin β 4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. *Cornea*. 2015;34(5):491–496.
<https://doi.org/10.1097/ICO.0000000000000379>
- [59] Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β 4 in healthy Chinese volunteers. *J Cell Mol Med*. 2021;25(17):8222–8228.
<https://doi.org/10.1111/jcmm.16693>